Amylyx Pharmaceuticals (AMLX) Competitors $5.76 -0.01 (-0.09%) As of 10:44 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AMLX vs. IDYA, SDGR, INDV, GLPG, APGE, BEAM, IMCR, TARS, BHC, and IRONShould you be buying Amylyx Pharmaceuticals stock or one of its competitors? The main competitors of Amylyx Pharmaceuticals include IDEAYA Biosciences (IDYA), Schrödinger (SDGR), Indivior (INDV), Galapagos (GLPG), Apogee Therapeutics (APGE), Beam Therapeutics (BEAM), Immunocore (IMCR), Tarsus Pharmaceuticals (TARS), Bausch Health Companies (BHC), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical products" industry. Amylyx Pharmaceuticals vs. IDEAYA Biosciences Schrödinger Indivior Galapagos Apogee Therapeutics Beam Therapeutics Immunocore Tarsus Pharmaceuticals Bausch Health Companies Disc Medicine Amylyx Pharmaceuticals (NASDAQ:AMLX) and IDEAYA Biosciences (NASDAQ:IDYA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations, risk and community ranking. Is AMLX or IDYA more profitable? IDEAYA Biosciences' return on equity of -26.74% beat Amylyx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Amylyx PharmaceuticalsN/A -36.97% -29.61% IDEAYA Biosciences N/A -26.74%-25.54% Does the media refer more to AMLX or IDYA? In the previous week, Amylyx Pharmaceuticals had 2 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 7 mentions for Amylyx Pharmaceuticals and 5 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 1.08 beat Amylyx Pharmaceuticals' score of 0.80 indicating that IDEAYA Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IDEAYA Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend AMLX or IDYA? Amylyx Pharmaceuticals presently has a consensus target price of $9.83, indicating a potential upside of 70.87%. IDEAYA Biosciences has a consensus target price of $54.27, indicating a potential upside of 143.48%. Given IDEAYA Biosciences' higher probable upside, analysts plainly believe IDEAYA Biosciences is more favorable than Amylyx Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amylyx Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.11IDEAYA Biosciences 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.93 Does the MarketBeat Community prefer AMLX or IDYA? IDEAYA Biosciences received 103 more outperform votes than Amylyx Pharmaceuticals when rated by MarketBeat users. Likewise, 71.86% of users gave IDEAYA Biosciences an outperform vote while only 70.18% of users gave Amylyx Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAmylyx PharmaceuticalsOutperform Votes4070.18% Underperform Votes1729.82% IDEAYA BiosciencesOutperform Votes14371.86% Underperform Votes5628.14% Which has more volatility and risk, AMLX or IDYA? Amylyx Pharmaceuticals has a beta of -0.59, indicating that its stock price is 159% less volatile than the S&P 500. Comparatively, IDEAYA Biosciences has a beta of 0.04, indicating that its stock price is 96% less volatile than the S&P 500. Do insiders and institutionals have more ownership in AMLX or IDYA? 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are owned by institutional investors. 11.7% of Amylyx Pharmaceuticals shares are owned by company insiders. Comparatively, 2.5% of IDEAYA Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has higher valuation and earnings, AMLX or IDYA? Amylyx Pharmaceuticals has higher earnings, but lower revenue than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmylyx Pharmaceuticals-$1.27M-403.31$49.27M-$3.11-1.85IDEAYA Biosciences$7M278.89-$274.48M-$3.59-6.21 SummaryIDEAYA Biosciences beats Amylyx Pharmaceuticals on 11 of the 18 factors compared between the two stocks. Get Amylyx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMLX vs. The Competition Export to ExcelMetricAmylyx PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$514.34M$6.85B$5.58B$8.67BDividend YieldN/A2.49%5.27%4.19%P/E Ratio-1.518.8227.2320.12Price / Sales-403.31263.82423.64161.29Price / Cash5.5165.8538.2534.64Price / Book0.906.657.114.72Net Income$49.27M$143.49M$3.23B$247.80M7 Day Performance16.97%4.70%3.67%2.77%1 Month Performance24.84%15.02%13.11%9.75%1 Year Performance230.75%5.96%32.12%15.01% Amylyx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMLXAmylyx Pharmaceuticals3.8024 of 5 stars$5.76-0.1%$9.83+70.9%+227.3%$514.34M$-1,272,000.00-1.51200IDYAIDEAYA Biosciences3.7926 of 5 stars$21.71-0.1%$54.27+150.0%-41.0%$1.90B$7M-6.5880Positive NewsAnalyst RevisionSDGRSchrödinger2.4234 of 5 stars$25.47+3.5%$32.80+28.8%+22.4%$1.87B$230.49M-10.88790INDVIndivior1.9958 of 5 stars$13.43-4.5%$15.00+11.7%-19.3%$1.85B$1.17B-38.371,164Positive NewsGLPGGalapagos0.801 of 5 stars$28.09+1.3%$25.33-9.8%+7.2%$1.85B$288.19M0.001,310Positive NewsAPGEApogee Therapeutics2.0673 of 5 stars$40.13-2.1%$94.60+135.7%-4.3%$1.85BN/A-16.5891BEAMBeam Therapeutics3.042 of 5 stars$18.17-2.2%$48.75+168.3%-25.9%$1.83B$63.58M-10.32510Analyst RevisionIMCRImmunocore2.8679 of 5 stars$36.07-3.2%$58.89+63.3%-11.2%$1.81B$333.58M-37.97320Positive NewsAnalyst RevisionHigh Trading VolumeTARSTarsus Pharmaceuticals2.8726 of 5 stars$43.11-1.8%$66.67+54.6%+27.0%$1.81B$233.67M-11.3150Positive NewsBHCBausch Health Companies4.5787 of 5 stars$4.88+2.5%$7.42+52.0%-19.5%$1.81B$9.73B-40.6619,900Positive NewsIRONDisc Medicine1.8624 of 5 stars$51.42+2.8%$98.80+92.1%+33.6%$1.78BN/A-12.9230Positive NewsInsider TradeAnalyst Revision Related Companies and Tools Related Companies IDEAYA Biosciences Competitors Schrödinger Competitors Indivior Competitors Galapagos Competitors Apogee Therapeutics Competitors Beam Therapeutics Competitors Immunocore Competitors Tarsus Pharmaceuticals Competitors Bausch Health Companies Competitors Disc Medicine Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMLX) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amylyx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amylyx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AMLX Stock Free AMLX Stock Alerts